{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:11:15Z","timestamp":1791562275210,"version":"4.3.4"},"reference-count":207,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurochemistry International"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.neuint.2013.06.005","type":"journal-article","created":{"date-parts":[[2013,6,19]],"date-time":"2013-06-19T11:47:38Z","timestamp":1371642458000},"page":"201-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":217,"title":["Biomarkers in Parkinson\u2019s disease (recent update)"],"prefix":"10.1016","volume":"63","author":[{"given":"Sushil","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn Seungyoun","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azza","family":"Khogali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Haidous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Chabenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Comfort","family":"Ojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriana","family":"Jelebinkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Kurdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuchair","family":"Ebadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuint.2013.06.005_b0005","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/JAD-2006-9309","article-title":"Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders","author":"Abdi","year":"2006","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuint.2013.06.005_b0010","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1586\/ern.12.144","article-title":"New concepts in the early and preclinical detection of Parkinson\u2019s disease: therapeutic implications","volume":"12","author":"Akhtar","year":"2012","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neuint.2013.06.005_b0015","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jbiotec.2011.08.004","article-title":"Proteomics in Parkinson\u2019s disease: an unbiased approach towards peripheral biomarkers and new therapies","volume":"156","author":"Alberio","year":"2011","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.neuint.2013.06.005_b0020","doi-asserted-by":"crossref","unstructured":"Alberio, T., Pippione, A.C., Zibetti, M., Olgiati, S., Cecconi, D., Comi, C., Lopiano, L., Fasano, M., 2012. Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson\u2019s disease. Sci. Rep. 2, 953.","DOI":"10.1038\/srep00953"},{"key":"10.1016\/j.neuint.2013.06.005_b0025","series-title":"Parkinson\u2019s disease plasma biomarkers: an automated literature analysis followed by experimental validation","author":"Alberio","year":"2013"},{"issue":"1","key":"10.1016\/j.neuint.2013.06.005_b0030","first-page":"72","article-title":"Parkinson\u2019s disease. Clinical and electrophysiological evaluation","volume":"21","author":"Al-Bunyan","year":"2000","journal-title":"Saudi Med. J."},{"key":"10.1016\/j.neuint.2013.06.005_b0035","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/npp.2008.172","article-title":"Target identification for CNS diseases by transcriptional profiling","volume":"34","author":"Altar","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuint.2013.06.005_b0040","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.clineuro.2004.10.011","article-title":"CSF biomarkers for mild cognitive impairment and early Alzheimer\u2019s disease","volume":"107","author":"Andreasen","year":"2005","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.neuint.2013.06.005_b0045","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.brainres.2009.11.085","article-title":"Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives","volume":"1319","author":"Arnal","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.neuint.2013.06.005_b0050","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000331490","article-title":"Parkinson\u2019s disease and dementia: a longitudinal study (DEMPARK)","volume":"37","author":"Balzer-Geldsetzer","year":"2011","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.neuint.2013.06.005_b0055","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/NEN.0b013e3182805c72","article-title":"Submandibular gland biopsy for the diagnosis of Parkinson disease","volume":"72","author":"Beach","year":"2013","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"Suppl. 3","key":"10.1016\/j.neuint.2013.06.005_b0060","first-page":"40","article-title":"Early diagnosis of Parkinson\u2019s disease","volume":"249","author":"Becker","year":"2002","journal-title":"J. Neurol."},{"issue":"Suppl. 2","key":"10.1016\/j.neuint.2013.06.005_b0065","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/j.rbp.2012.07.002","article-title":"New molecular targets for PET and SPECT imaging in neurodegenerative diseases","volume":"34","author":"Benadiba","year":"2012","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.neuint.2013.06.005_b0070","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1517\/17460441.2012.659661","article-title":"Gene expression profiling and therapeutic interventions in neurodegenerative diseases: a comprehensive study on potentiality and limits","volume":"7","author":"Benetti","year":"2012","journal-title":"Expert Opin. Drug Discovery"},{"key":"10.1016\/j.neuint.2013.06.005_b0075","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.pnpbp.2006.12.025","article-title":"Cerebral glucose utilization and platelet mitochondrial complex I activity in schizophrenia: a FDG-PET study","volume":"31","author":"Ben-Shachar","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuint.2013.06.005_b0080","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S1353-8020(11)70008-6","article-title":"Misfolded \u03b1-Syn and toll-like receptors: therapeutic targets for Parkinson\u2019s disease","volume":"18","author":"Beraud","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuint.2013.06.005_b0085","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11481-012-9401-0","article-title":"Microglial activation and antioxidant responses induced by the Parkinson\u2019s disease protein \u03b1-Syn","volume":"8","author":"B\u00e9raud","year":"2013","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.neuint.2013.06.005_b0090","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-3-211-33328-0_14","article-title":"Marker for a preclinical diagnosis of Parkinson\u2019s disease as a basis for neuroprotection","volume":"71","author":"Berg","year":"2006","journal-title":"J. Neural Transm. Suppl."},{"key":"10.1016\/j.neuint.2013.06.005_b0095","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000113682","article-title":"Biomarkers for the early detection of Parkinson\u2019s and Alzheimer\u2019s disease","volume":"5","author":"Berg","year":"2008","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.neuint.2013.06.005_b0100","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-006-0578-x","article-title":"The debate over dopamine\u2019s role in reward: the case for incentive salience","volume":"191","author":"Berridge","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuint.2013.06.005_b0105","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1460-9568.2012.07990.x","article-title":"From prediction error to incentive salience: mesolimbic computation of reward motivation","volume":"35","author":"Berridge","year":"2012","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuint.2013.06.005_b0110","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1212\/WNL.0b013e31827b90d1","article-title":"Naturally occurring \u03b1-Syn autoantibody levels are lower in patients with Parkinson disease","volume":"80","author":"Besong-Agbo","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neuint.2013.06.005_b0115","doi-asserted-by":"crossref","first-page":"33691","DOI":"10.1074\/jbc.M112.379792","article-title":"Novel one-step immunoassays to quantify \u03b1-Syn: applications for biomarker development and high-throughput screening","volume":"287","author":"Bidinosti","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuint.2013.06.005_b0120","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1602\/neurorx.1.2.213","article-title":"Cerebrospinal fluid protein biomarkers for Alzheimer\u2019s disease","volume":"1","author":"Blennow","year":"2004","journal-title":"NeuroRx"},{"key":"10.1016\/j.neuint.2013.06.005_b0130","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/02791072.2012.685407","article-title":"The addictive brain: all roads lead to dopamine","volume":"44","author":"Blum","year":"2012","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.neuint.2013.06.005_b0135","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1749-6632.2009.05115.x","article-title":"REM sleep behavior disorder: updated review of the core features, the RBD-Neurodegenerative Disease Association, evolving concepts, controversies, and future directions","volume":"1184","author":"Boeve","year":"2010","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.neuint.2013.06.005_b0140","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1601-183X.2007.00342.x","article-title":"Genetic findings in Parkinson\u2019s disease and translation into treatment: a leading role for mitochondria?","volume":"7","author":"Bogaerts","year":"2008","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.neuint.2013.06.005_b0145","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1074\/jbc.M407384200","article-title":"TRPC-1-mediated inhibition of MPP+ toxicity in human SH-S-Y5Y neuroblastoma cells","volume":"280","author":"Bollimuntha","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuint.2013.06.005_b0150","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.yfrne.2009.04.014","article-title":"Neuroprotective actions of sex steroids in Parkinson\u2019s disease","volume":"30","author":"Bourque","year":"2009","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.neuint.2013.06.005_b0155","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1093\/hmg\/dds089","article-title":"Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis","volume":"21","author":"Bras","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuint.2013.06.005_b0160","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00702-012-0928-2","article-title":"Non-motor symptoms of Parkinson\u2019s disease: the patient\u2019s perspective","volume":"120","author":"Breen","year":"2013","journal-title":"J. Neural Transm."},{"issue":"Suppl. 3","key":"10.1016\/j.neuint.2013.06.005_b0165","doi-asserted-by":"crossref","first-page":"S268","DOI":"10.1016\/S1353-8020(08)70015-4","article-title":"Assessment of Parkinson\u2019s disease with imaging","volume":"13","author":"Brooks","year":"2007","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuint.2013.06.005_b0170","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.pneurobio.2011.08.009","article-title":"Imaging biomarkers in Parkinson\u2019s disease","volume":"95","author":"Brooks","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuint.2013.06.005_b0175","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1016-8478(23)17545-5","article-title":"Altered complexin expression in psychiatric and neurological disorders: cause or consequence?","volume":"25","author":"Brose","year":"2008","journal-title":"Mol. Cells"},{"key":"10.1016\/j.neuint.2013.06.005_b0180","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/01.wco.0000247607.34697.a2","article-title":"Cortical Lewy body disease and Parkinson\u2019s disease dementia","volume":"19","author":"Burn","year":"2006","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.neuint.2013.06.005_b0185","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1089\/ars.2012.4742","article-title":"Redox proteomics","volume":"17","author":"Butterfield","year":"2012","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.neuint.2013.06.005_b0190","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/mds.21288","article-title":"Magnetic resonance spectroscopic evidence for presupplementary motor area neuronal dysfunction in Parkinson\u2019s disease","volume":"22","author":"Camicioli","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuint.2013.06.005_b0195","first-page":"1","article-title":"Gender differences in Parkinson\u2019s disease: focus on plasma alpha-Syn","author":"Caranci","year":"2013","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neuint.2013.06.005_b0200","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5603\/NMR.2013.0007","article-title":"Neurological applications for myocardial MIBG scintigraphy","volume":"16","author":"Cascini","year":"2013","journal-title":"Nucl. Med. Rev. Cent. East. Eur."},{"key":"10.1016\/j.neuint.2013.06.005_b0205","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1586\/ern.10.54","article-title":"Using \u2018omics\u2019 to define pathogenesis and biomarkers of Parkinson\u2019s disease","volume":"10","author":"Caudle","year":"2010","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neuint.2013.06.005_b0210","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/WCO.0b013e3283461723","article-title":"Diagnostic markers for Parkinson\u2019s disease","volume":"24","author":"Chahine","year":"2011","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.neuint.2013.06.005_b0215","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jocn.2012.05.052","article-title":"The role of the Ala746Thr variant in the ATP13A2 gene among Chinese patients with Parkinson\u2019s disease","volume":"20","author":"Chan","year":"2013","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.neuint.2013.06.005_b0220","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.clinbiochem.2011.01.002","article-title":"Component as a plasma marker for Parkinson\u2019s disease identified by a proteomic approach","volume":"44","author":"Chen","year":"2011","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.neuint.2013.06.005_b0225","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ana.21995","article-title":"Clinical progression in Parkinson disease and the neurobiology of axons","volume":"67","author":"Cheng","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuint.2013.06.005_b0230","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1021\/pr070546l","article-title":"Mitochondrial dysfunction, oxidative stress, and apoptosis revealed by proteomic and transcriptomic analyses of the striata in two mouse models of Parkinson\u2019s disease","volume":"7","author":"Chin","year":"2008","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.neuint.2013.06.005_b0235","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1093\/brain\/awp263","article-title":"Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson\u2019s disease dementia","volume":"132","author":"Compta","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.neuint.2013.06.005_b0240","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.neuro.2011.01.003","article-title":"\u03b1-Syn, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease","volume":"32","author":"Covy","year":"2011","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.neuint.2013.06.005_b0245","first-page":"697","article-title":"Differentiation and diagnosis of tremor","volume":"83","author":"Crawford","year":"2011","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.neuint.2013.06.005_b0255","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/jnr.20412","article-title":"Regulation of striatal preproenkephalin mRNA levels in MPTP-lesioned mice treated with estradiol","volume":"80","author":"D\u2019Astous","year":"2005","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neuint.2013.06.005_b0260","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.4161\/auto.21011","article-title":"Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove","volume":"8","author":"Dehay","year":"2012","journal-title":"Autophagy"},{"key":"10.1016\/j.neuint.2013.06.005_b0265","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2217\/bmm.12.46","article-title":"Recommendations to standardize preanalytical confounding factors in Alzheimer\u2019s and Parkinson\u2019s disease cerebrospinal fluid biomarkers: an update","volume":"6","author":"Del Campo","year":"2012","journal-title":"Biomark Med."},{"key":"10.1016\/j.neuint.2013.06.005_b0270","doi-asserted-by":"crossref","first-page":"391438","DOI":"10.1155\/2012\/391438","article-title":"Protein clearance mechanisms of alpha-Syn and amyloid-Beta in lewy body disorders","volume":"2012","author":"Deleidi","year":"2012","journal-title":"Int. J. Alzheimers Dis."},{"key":"10.1016\/j.neuint.2013.06.005_b0280","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/mds.23948","article-title":"Parkinson\u2019s disease and \u03b1-Syn expression","volume":"26","author":"Devine","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuint.2013.06.005_b0285","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/mds.25352","article-title":"Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson\u2019s disease?","volume":"28","author":"Duncan","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuint.2013.06.005_b0295","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1177\/153537020623100919","article-title":"Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson\u2019s disease","volume":"231","author":"Ebadi","year":"2006","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.neuint.2013.06.005_b0305","series-title":"Parkinson\u2019s Disease","article-title":"Weaver mutant mouse in progression of neurodegeneration in Parkinson\u2019s disease","author":"Ebadi","year":"2004"},{"key":"10.1016\/j.neuint.2013.06.005_b0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1389450110607011513","article-title":"Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases","volume":"7","author":"Ebadi","year":"2006","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.neuint.2013.06.005_b0345","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrneurol.2009.135","article-title":"Biological fluid biomarkers in neurodegenerative parkinsonism","volume":"5","author":"Eller","year":"2009","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuint.2013.06.005_b0350","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1517\/17460441.2012.659661","article-title":"Gene expression profiling and therapeutic interventions in neurodegenerative diseases: a comprehensive study on potentiality and limits","volume":"7","author":"Federico","year":"2012","journal-title":"Expert Opin. Drug Discovery"},{"key":"10.1016\/j.neuint.2013.06.005_b0360","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.bcp.2011.01.021","article-title":"Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer\u2019s disease and neuropsychiatric translational medicine","volume":"81","author":"Flood","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuint.2013.06.005_b0365","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1155\/2006\/202938","article-title":"Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods","volume":"22","author":"Fonteh","year":"2006","journal-title":"Dis. Markers"},{"key":"10.1016\/j.neuint.2013.06.005_b0370","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/syn.21584","article-title":"Detection of ischemic neuronal damage with [18F]BMS-747158-02, a mitochondrial complex-1 positron emission tomography ligand: small animal PET study in rat brain","volume":"66","author":"Fukumoto","year":"2012","journal-title":"Synapse"},{"key":"10.1016\/j.neuint.2013.06.005_b0375","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/RLU.0b013e318279b991","article-title":"Regions of interest-based discriminant analysis of DaTSCAN SPECT and FDG-PET for the classification of dementia","volume":"38","author":"Garibotto","year":"2013","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.neuint.2013.06.005_b0380","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/mds.23637","article-title":"Milestones in PD genetics","volume":"26","author":"Gasser","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuint.2013.06.005_b0385","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000113683","article-title":"The early detection of Parkinson\u2019s disease: unmet needs","volume":"5","author":"Gerlach","year":"2008","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.neuint.2013.06.005_b0390","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00702-011-0682-x","article-title":"Biomarker candidates of neurodegeneration in Parkinson\u2019s disease for the evaluation of disease-modifying therapeutics","volume":"119","author":"Gerlach","year":"2012","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neuint.2013.06.005_b0395","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/sj.mp.4001579","article-title":"MR-based in vivo hippocampal volumetrics: 2. Findings in neuropsychiatric disorders","volume":"10","author":"Geuze","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuint.2013.06.005_b0400","first-page":"224","article-title":"Imaging beyond the striatonigral dopaminergic system in Parkinson\u2019s disease","volume":"15","author":"Giza","year":"2012","journal-title":"Hell J. Nucl. Med."},{"key":"10.1016\/j.neuint.2013.06.005_b0405","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.parkreldis.2008.01.010","article-title":"Biomarkers to detect central dopaminergic deficiency and distinguish from multiple system atrophy","volume":"14","author":"Goldstein","year":"2008","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuint.2013.06.005_b0410","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jns.2011.04.011","article-title":"Autonomic dysfunction in PD: a window to early detection?","volume":"310","author":"Goldstein","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuint.2013.06.005_b0415","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/brain\/aws055","article-title":"Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson\u2019s disease and other Synopathies","volume":"135","author":"Goldstein","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.neuint.2013.06.005_b0420","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/j.1471-4159.2012.07924.x","article-title":"Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson\u2019s disease","volume":"123","author":"Goldstein","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuint.2013.06.005_b0425","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10286-011-0136-4","article-title":"Sympathetic noradrenergic before striatal dopaminergic denervation: relevance to Braak staging of Synopathy","volume":"22","author":"Goldstein","year":"2012","journal-title":"Clin. Auton. Res."},{"key":"10.1016\/j.neuint.2013.06.005_b0430","first-page":"85","article-title":"Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia","volume":"80","author":"Gomperts","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuint.2013.06.005_b0435","doi-asserted-by":"crossref","first-page":"13","DOI":"10.15690\/vramn.v67i9.401","article-title":"The application of nuclear medicine imaging in neurology, neurosurgery and psychiatry","volume":"9","author":"Granov","year":"2012","journal-title":"Vestn. Ross. Akad. Med. Nauk"},{"key":"10.1016\/j.neuint.2013.06.005_b0440","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/cr.2009.131","article-title":"Proteomic analysis of the cerebrospinal fluid of Parkinson\u2019s disease patients","volume":"19","author":"Guo","year":"2009","journal-title":"Cell Res."},{"key":"10.1016\/j.neuint.2013.06.005_b0445","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1468-1331.2007.01727.x","article-title":"Brain serotonin transporter binding in non-depressed patients with Parkinson\u2019s disease","volume":"14","author":"Guttman","year":"2007","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.neuint.2013.06.005_b0450","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","article-title":"Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or parkinsonian disorders","volume":"69","author":"Hall","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuint.2013.06.005_b0455","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.nurt.2008.10.033","article-title":"Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"6","author":"Halperin","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuint.2013.06.005_b0460","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuron.2010.10.014","article-title":"Genetic analysis of pathways to Parkinson disease","volume":"68","author":"Hardy","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.neuint.2013.06.005_b0465","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/ncpneuro0924","article-title":"Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis","volume":"4","author":"Henchcliffe","year":"2008","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"10.1016\/j.neuint.2013.06.005_b0470","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1515\/CCLM.2007.310","article-title":"Biomarkers of folate and vitamin B(12) status in cerebrospinal fluid","volume":"45","author":"Herrmann","year":"2007","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.neuint.2013.06.005_b0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4061\/2011\/842475","article-title":"Bridging molecular genetics and biomarkers in Lewy body and related disorders","volume":"2011","author":"Ho","year":"2011","journal-title":"Int. J. Alzheimers Dis."},{"key":"10.1016\/j.neuint.2013.06.005_b0480","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1111\/j.1460-9568.2012.08198.x","article-title":"Long-range temporal correlations in the subthalamic nucleus of patients with Parkinson\u2019s disease","volume":"36","author":"Hohlefeld","year":"2012","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuint.2013.06.005_b0485","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00401-012-1013-5","article-title":"The genetics and neuropathology of Parkinson\u2019s disease","volume":"124","author":"Houlden","year":"2012","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuint.2013.06.005_b0490","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/biof.552210152","article-title":"Promoting effect and recovery activity from physical stress of the fruit of Morus alba","volume":"21","author":"Hwang","year":"2004","journal-title":"Biofactors"},{"key":"10.1016\/j.neuint.2013.06.005_b0500","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/mds.23795","article-title":"Neuropathology of sporadic Parkinson\u2019s disease: evaluation and changes of concepts","volume":"27","author":"Jellinger","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuint.2013.06.005_b0505","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.molbrainres.2004.10.003","article-title":"Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson\u2019s disease","volume":"134","author":"Jin","year":"2005","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.neuint.2013.06.005_b0510","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.neubiorev.2010.06.007","article-title":"Potential mechanisms underlying anxiety and depression in Parkinson\u2019s disease: consequences of L-DOPA treatment","volume":"35","author":"Karen","year":"2011","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuint.2013.06.005_b0515","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/437025","article-title":"\u03b1-Syn as CSF and blood biomarker of dementia with Lewy bodies","volume":"2012","author":"Kasuga","year":"2012","journal-title":"Int. J. Alzheimers Dis."},{"key":"10.1016\/j.neuint.2013.06.005_b0520","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jns.2011.07.012","article-title":"Dopaminergic dysregulation syndrome in Parkinson\u2019s disease","volume":"310","author":"Katzenschlager","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuint.2013.06.005_b0535","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/WCO.0b013e3280adc943","article-title":"Therapeutic approaches to inflammation in neurodegenerative disease","volume":"20","author":"Klegeris","year":"2007","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.neuint.2013.06.005_b0540","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/WCO.0b013e3281e6692b","article-title":"Impact of recent genetic findings in Parkinson\u2019s disease","volume":"20","author":"Klein","year":"2007","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.neuint.2013.06.005_b0555","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1460-9568.2011.07933.x","article-title":"Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T Syn mouse model","volume":"35","author":"Kohl","year":"2012","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuint.2013.06.005_b0560","first-page":"27","article-title":"When does Parkinson\u2019s disease begin?","volume":"42","author":"Koller","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.neuint.2013.06.005_b0565","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.tics.2009.08.006","article-title":"Towards a functional neuroanatomy of pleasure and happiness","volume":"13","author":"Kringelbach","year":"2009","journal-title":"Trends Cogn. Sci."},{"key":"10.1016\/j.neuint.2013.06.005_b0570","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jprot.2010.11.010","article-title":"Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics","volume":"74","author":"Kroksveen","year":"2011","journal-title":"J. Proteomics"},{"key":"10.1016\/j.neuint.2013.06.005_b0575","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.brainres.2011.12.028","article-title":"Involvement of NADPH oxidase and glutathione in zinc-induced dopaminergic neurodegeneration in rats: similarity with paraquat neurotoxicity","volume":"1438","author":"Kumar","year":"2012","journal-title":"Brain Res."},{"key":"10.1016\/j.neuint.2013.06.005_b0585","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1034\/j.1600-0447.2002.02045.x","article-title":"Markers for depression in Parkinson\u2019s disease","volume":"106","author":"Leentjens","year":"2002","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.neuint.2013.06.005_b0590","doi-asserted-by":"crossref","first-page":"163","DOI":"10.31887\/DCNS.2006.8.2\/bleonard","article-title":"Changes in the immune system in depression and dementia: causal or coincidental effects?","volume":"8","author":"Leonard","year":"2006","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.neuint.2013.06.005_b0595","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1750-3639.2007.00048.x","article-title":"Proteomic identification of novel proteins in cortical Lewy bodies","volume":"17","author":"Leverenz","year":"2007","journal-title":"Brain Pathol."},{"key":"10.1016\/j.neuint.2013.06.005_b0600","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000323427","article-title":"Matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry combined with magnetic beads for detecting serum protein biomarkers in Parkinson\u2019s disease","volume":"65","author":"Li","year":"2011","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.neuint.2013.06.005_b0605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2012.02.018","article-title":"Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective","volume":"317","author":"Li","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuint.2013.06.005_b0610","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jprot.2009.07.007","article-title":"Proteomics in human Parkinson\u2019s disease research","volume":"73","author":"Licker","year":"2009","journal-title":"J. Proteomics"},{"key":"10.1016\/j.neuint.2013.06.005_b0615","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00702-010-0553-x","article-title":"Relation of risk factors and putative premotor markers for Parkinson\u2019s disease","volume":"118","author":"Liepelt-Scarfone","year":"2011","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neuint.2013.06.005_b0620","first-page":"954","article-title":"DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease","volume":"2","author":"Lin","year":"2012","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.neuint.2013.06.005_b0625","first-page":"113","article-title":"Neuroprotection in Parkinson\u2019s disease: analysis though group of experts\u2019 methodology","volume":"24","author":"Linazasoro","year":"2009","journal-title":"Neurologia"},{"key":"10.1016\/j.neuint.2013.06.005_b0630","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/978-1-62703-071-7_7","article-title":"Cytokines as potential biomarkers for Parkinson\u2019s disease: a multiplex approach","volume":"934","author":"Litteljohn","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.neuint.2013.06.005_b0635","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.bbrc.2008.08.142","article-title":"Striatal 19S Rpt6 deficit is related to alpha-Syn accumulation in MPTP-treated mice","volume":"376","author":"Liu","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuint.2013.06.005_b0640","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.brainresbull.2012.09.017","article-title":"The zebrafish homologue of Parkinson\u2019s disease ATP13A2 is essential for embryonic survival","volume":"90","author":"Lopes da Fonseca","year":"2013","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuint.2013.06.005_b0645","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1349-7006.2007.00395.x","article-title":"Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome","volume":"98","author":"Loukopoulos","year":"2007","journal-title":"Cancer Sci."},{"key":"10.1016\/j.neuint.2013.06.005_b0650","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1101\/lm.54603","article-title":"BDNF and activity-dependent synaptic modulation","volume":"10","author":"Lu","year":"2003","journal-title":"Learn. Mem."},{"key":"10.1016\/j.neuint.2013.06.005_b0655","first-page":"41","article-title":"Lithium-mediated protection against ethanol neurotoxicity","volume":"4","author":"Luo","year":"2010","journal-title":"Front Neurosci."},{"key":"10.1016\/j.neuint.2013.06.005_b0660","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4137\/BMI.S11422","article-title":"Arizona Parkinson\u2019s Disease Consortium. Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson\u2019s disease cases lacking Alzheimer\u2019s disease pathology","volume":"8","author":"Maarouf","year":"2013","journal-title":"Biomark Insights"},{"key":"10.1016\/j.neuint.2013.06.005_b0665","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4161\/pri.18665","article-title":"Nanopore analysis: an emerging technique for studying the folding and misfolding of proteins","volume":"6","author":"Madampage","year":"2012","journal-title":"Prion"},{"key":"10.1016\/j.neuint.2013.06.005_b0670","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/S1474-4422(09)70291-1","article-title":"Progression of Parkinson\u2019s disease in the clinical phase: potential markers","volume":"8","author":"Maetzler","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuint.2013.06.005_b0675","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1002\/ana.21602","article-title":"Biomarkers for Parkinson\u2019s [corrected] disease: tools to assess Parkinson\u2019s disease onset and progression","volume":"64","author":"Marek","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuint.2013.06.005_b0680","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","article-title":"The Parkinson Progression Marker Initiative (PPMI)","volume":"95","author":"Marek","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuint.2013.06.005_b0685","doi-asserted-by":"crossref","first-page":"11865","DOI":"10.1523\/JNEUROSCI.3695-07.2007","article-title":"The roles of kinases in familial Parkinson\u2019s disease","volume":"27","author":"Mark","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuint.2013.06.005_b0690","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/nrneurol.2013.47","article-title":"Parkinson disease: new guidelines for diagnosis of Parkinson disease","volume":"9","author":"Mart\u00ed","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuint.2013.06.005_b0695","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1096\/fj.08-125443","article-title":"Glutathione \u2013 a review on its role and significance in Parkinson\u2019s disease","volume":"23","author":"Martin","year":"2009","journal-title":"FASEB J."},{"key":"10.1016\/j.neuint.2013.06.005_b0705","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1586\/erm.10.86","article-title":"Exploiting the potential of molecular profiling in Parkinson\u2019s disease: current practice and future probabilities","volume":"10","author":"Mellick","year":"2010","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"6","key":"10.1016\/j.neuint.2013.06.005_b0710","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2217\/14796708.3.6.669","article-title":"Update on the functional biology of Lrrk2","volume":"3","author":"Melrose","year":"2008","journal-title":"Future Neurol."},{"key":"10.1016\/j.neuint.2013.06.005_b0720","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1179\/1743132812Y.0000000092","article-title":"Neuroproteomics: an insight into ALS","volume":"34","author":"Mendon\u00e7a","year":"2012","journal-title":"Neurol. Res."},{"key":"10.1016\/j.neuint.2013.06.005_b0725","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/brain\/awh198","article-title":"Biomarker and Parkinson\u2019s disease","volume":"127","author":"Michell","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.neuint.2013.06.005_b0730","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/archneur.59.10.1553","article-title":"The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias","volume":"59","author":"Mignot","year":"2002","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuint.2013.06.005_b0735","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jns.2012.03.023","article-title":"Coenzyme Q10 deficiency in patients with Parkinson\u2019s disease","volume":"318","author":"Mischley","year":"2012","journal-title":"J. Neurol. Sci."},{"issue":"10","key":"10.1016\/j.neuint.2013.06.005_b0740","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/mds.22510","article-title":"Neurochemical biomarkers in the differential diagnosis of movement disorders","volume":"24","author":"Mollenhauer","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuint.2013.06.005_b0745","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.neulet.2012.11.004","article-title":"Total CSF \u03b1-Syn is lower in de novo Parkinson patients than in healthy subjects","volume":"532","author":"Mollenhauer","year":"2013","journal-title":"Neurosci. Lett."},{"issue":"7","key":"10.1016\/j.neuint.2013.06.005_b0750","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1750-1326-7-26","article-title":"A molecular signature in blood identifies early Parkinson\u2019s disease","volume":"31","author":"Molochnikov","year":"2012","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuint.2013.06.005_b0755","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11910-010-0144-0","article-title":"Biomarkers in Parkinson\u2019s disease","volume":"10","author":"Morgan","year":"2010","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.neuint.2013.06.005_b0760","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/mds.23792","article-title":"Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson\u2019s disease","volume":"26","author":"Morley","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuint.2013.06.005_b0765","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.nbd.2011.12.046","article-title":"MicroRNAs in Parkinson\u2019s disease","volume":"46","author":"Mouradian","year":"2012","journal-title":"Neurobiol. Dis."},{"issue":"10","key":"10.1016\/j.neuint.2013.06.005_b0770","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/mds.20573","article-title":"Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra","volume":"20","author":"Noureddine","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuint.2013.06.005_b0775","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1038\/npp.2012.19","article-title":"Dopamine modulates reward system activity during subconscious processing of sexual stimuli","volume":"37","author":"Oei","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuint.2013.06.005_b0780","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.neubiorev.2012.01.004","article-title":"Using Support Vector Machine to identify imaging biomarkers of neurological and psychiatric disease: a critical review","volume":"36","author":"Orr\u00f9","year":"2012","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuint.2013.06.005_b0785","doi-asserted-by":"crossref","first-page":"e19239","DOI":"10.1371\/journal.pone.0019239","article-title":"Sim1 is a novel regulator in the differentiation of mouse dorsal raphe serotonergic neurons","volume":"6","author":"Osterberg","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.neuint.2013.06.005_b0790","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1021\/pr700630x","article-title":"Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption\/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF\/TOF) platform","volume":"7","author":"Pan","year":"2008","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.neuint.2013.06.005_b0795","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ana.22687","article-title":"PD GWAS Consortium. Meta-analysis of Parkinson\u2019s disease: identification of a novel locus, RIT2","volume":"71","author":"Pankratz","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuint.2013.06.005_b0800","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2147\/NDT.S32302","article-title":"Review: management of Parkinson\u2019s disease","volume":"9","author":"Pedrosa","year":"2013","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.neuint.2013.06.005_b0805","first-page":"155","article-title":"Application of magnetic resonance spectroscopy in the study of brain disease","volume":"30","author":"P\u00e9rez-G\u00f3mez","year":"2000","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuint.2013.06.005_b0810","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bbamem.2011.07.032","article-title":"Biophysics of \u03b1-Syn membrane interactions","volume":"1818","author":"Pfefferkorn","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuint.2013.06.005_b0815","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.neuroscience.2013.01.025","article-title":"Steroids hormones and BDNF","volume":"239","author":"Pluchino","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuint.2013.06.005_b0820","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1742-1241.2008.01869.x","article-title":"Diagnosis and management of Parkinson\u2019s disease dementia","volume":"62","author":"Poewe","year":"2008","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.neuint.2013.06.005_b0825","first-page":"400","article-title":"Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson\u2019s disease","volume":"136","author":"Politis","year":"2013","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.neuint.2013.06.005_b0830","first-page":"845","article-title":"Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder","volume":"66","author":"Postuma","year":"2006","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuint.2013.06.005_b0835","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1136\/jnnp.2009.174748","article-title":"Clinical prediction of Parkinson\u2019s disease: planning for the age of neuroprotection","volume":"81","author":"Postuma","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuint.2013.06.005_b0840","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/mds.24996","article-title":"Identifying prodromal Parkinson\u2019s disease: pre-motor disorders in Parkinson\u2019s disease","volume":"27","author":"Postuma","year":"2012","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.neuint.2013.06.005_b0845","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mds.24962","article-title":"The neuropathology of genetic Parkinson\u2019s disease","volume":"27","author":"Poulopoulos","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuint.2013.06.005_b0850","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.neuroimage.2011.10.018","article-title":"Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion","volume":"59","author":"Power","year":"2012","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuint.2013.06.005_b0855","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.nbd.2009.02.019","article-title":"Metabolomics tools for identifying biomarkers for neuropsychiatric diseases","volume":"35","author":"Quinones","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuint.2013.06.005_b0860","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/iub.189","article-title":"Oxidized proteins: mechanisms of removal and consequences of accumulation","volume":"61","author":"Rachael","year":"2009","journal-title":"IUBMB Life"},{"issue":"1","key":"10.1016\/j.neuint.2013.06.005_b0865","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.mito.2012.10.004","article-title":"PINK1 parkinsonism and Parkinson disease: distinguishable brain mitochondrial function and metabolomics","volume":"13","author":"Rango","year":"2013","journal-title":"Mitochondrion"},{"key":"10.1016\/j.neuint.2013.06.005_b0870","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/mds.22690","article-title":"Parkinson Study Group LABS-PD Investigators. A longitudinal program for biomarker development in Parkinson\u2019s disease: a feasibility study","volume":"24","author":"Ravina","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuint.2013.06.005_b0875","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/ALN.0b013e3181d47604","article-title":"Statistical evaluation of a biomarker","volume":"112","author":"Ray","year":"2010","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuint.2013.06.005_b0880","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1440-1789.2008.00916.x","article-title":"What determines the molecular composition of abnormal protein aggregates in neurodegenerative disease?","volume":"28","author":"Richard","year":"2008","journal-title":"Neuropathology"},{"issue":"4","key":"10.1016\/j.neuint.2013.06.005_b0885","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1586\/epr.10.40","article-title":"Understanding the molecular basis of Parkinson\u2019s disease, identification of biomarkers and routes to therapy","volume":"7","author":"Robinson","year":"2010","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.neuint.2013.06.005_b0890","series-title":"Towards New Therapies for Parkinson\u2019s Disease","first-page":"58","article-title":"Alpha-Syn and the immune response in Parkinson\u2019s disease","author":"Roodveldt","year":"2011"},{"key":"10.1016\/j.neuint.2013.06.005_b0895","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00702-013-1007-z","article-title":"Different diagnostic criteria for Parkinson disease: what are the pitfalls?","volume":"120","author":"Roongroj","year":"2013","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neuint.2013.06.005_b1210","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.clinimag.2013.02.001","article-title":"Clinical MRI for iron detection in Parkinson\u2019s disease","volume":"37","author":"Rossi","year":"2013","journal-title":"Clin. Imaging"},{"key":"10.1016\/j.neuint.2013.06.005_b0905","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1755-5949.2010.00163.x","article-title":"Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders","volume":"16","author":"S\u00e1nchez","year":"2010","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.neuint.2013.06.005_b0915","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2217\/bmm.10.93","article-title":"Biomarker research in Parkinson\u2019s disease: objective measures needed for patient stratification in future cause-directed trials","volume":"4","author":"Schlossmacher","year":"2010","journal-title":"Biomark Med."},{"key":"10.1016\/j.neuint.2013.06.005_b0920","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1093\/hmg\/ddt057","article-title":"Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited \u00e1-Syn accumulation and age-dependent sensorimotor deficits","volume":"22","author":"Schultheis","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuint.2013.06.005_b0925","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.neuint.2012.12.014","article-title":"Effect of diet on serotonergic neurotransmission in depression","volume":"62","author":"Shabbir","year":"2013","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuint.2013.06.005_b0930","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneumeth.2004.02.003","article-title":"An improved method for analyzing coenzyme Q homologues and multiple detection of rare biological samples","volume":"137","author":"Sharma","year":"2004","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuint.2013.06.005_b0935","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.molbrainres.2005.05.018","article-title":"Distribution kinetics of 18F-DOPA in weaver mutant mice","volume":"139","author":"Sharma","year":"2005","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.neuint.2013.06.005_b0940","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.neuint.2007.08.011","article-title":"SPECT Neuroimaging in Translational Research of CNS Disorders","volume":"52","author":"Sharma","year":"2008","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuint.2013.06.005_b0950","first-page":"50","article-title":"Therapeutic potential of metallothioneins as anti-inflammatory agents in polysubstance abuse","volume":"2","author":"Sharma","year":"2011","journal-title":"J. Inst. Integr. Omics Appl. Biotechnol. (IIOAB J.)"},{"key":"10.1016\/j.neuint.2013.06.005_b0955","first-page":"98","article-title":"Metallothioneins as early & sensitive biomarkers of redox signaling in neurodegenerative disorders","volume":"2","author":"Sharma","year":"2011","journal-title":"J. Inst. Integr. Omics Appl. Biotechnol. (IIOAB J.)"},{"key":"10.1016\/j.neuint.2013.06.005_b0965","series-title":"System Biology of Oxidative Stress","first-page":"1","article-title":"Antioxidants as potential therapeutics in Parkinson\u2019s disease","author":"Sharma","year":"2014"},{"key":"10.1016\/j.neuint.2013.06.005_b0970","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1023\/B:NEUR.0000011327.23739.1b","article-title":"The neuroprotective actions of selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)-induced apoptosis in dopaminergic neurons","volume":"32","author":"Sharma","year":"2003","journal-title":"J. Neurocytol."},{"key":"10.1016\/j.neuint.2013.06.005_b0975","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0076-6879(04)82027-5","article-title":"Neuroprotective actions of coenzyme Q10 in Parkinson\u2019s disease","volume":"382","author":"Sharma","year":"2004","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.neuint.2013.06.005_b0980","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.brainresbull.2005.11.019","article-title":"Complex-1 activity and 18F-DOPA uptake in genetically engineered mouse model of Parkinson\u2019s disease and the neuroprotective role of coenzyme Q10","volume":"70","author":"Sharma","year":"2006","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuint.2013.06.005_b0985","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.2147\/IJN.S42019","article-title":"Clinical significance of metallothioneins in cell therapy and nanomedicine","volume":"8","author":"Sharma","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.neuint.2013.06.005_b1000","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.nbd.2008.09.004","article-title":"Biomarker discovery in neurodegenerative diseases: a proteomic approach","volume":"35","author":"Shi","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuint.2013.06.005_b1005","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1750-3639.2009.00370.x","article-title":"Biomarkers for cognitive impairment in Parkinson disease","volume":"20","author":"Shi","year":"2010","journal-title":"Brain Pathol."},{"key":"10.1016\/j.neuint.2013.06.005_b1010","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/ana.22311","article-title":"Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression","volume":"69","author":"Shi","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuint.2013.06.005_b1015","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/WCO.0b013e3283550c0d","article-title":"Biomarkers in Parkinson\u2019s disease: an update","volume":"25","author":"Shtilbans","year":"2012","journal-title":"Curr. Opin. Neurol."},{"issue":"7","key":"10.1016\/j.neuint.2013.06.005_b1020","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1212\/WNL.0b013e31828250d6","article-title":"Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease","volume":"80","author":"Sierra","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neuint.2013.06.005_b1030","series-title":"Diagnosis and Treatment of Parkinson\u2019s disease","first-page":"21","article-title":"Impact of dopamine transporter scan in Parkinson\u2019s disease","author":"Speigel","year":"2011"},{"issue":"5","key":"10.1016\/j.neuint.2013.06.005_b1035","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/1756285611406166","article-title":"Therapeutic potential of melatonin and its analogs in Parkinson\u2019s disease: focus on sleep and neuroprotection","volume":"4","author":"Srinivasan","year":"2011","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"1","key":"10.1016\/j.neuint.2013.06.005_b1040","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1586\/epr.09.91","article-title":"Proteomics in Parkinson\u2019s disease: current trends, translational snags and future possibilities","volume":"7","author":"Srivastava","year":"2010","journal-title":"Expert Rev. Proteomics"},{"issue":"2","key":"10.1016\/j.neuint.2013.06.005_b1050","first-page":"00939","article-title":"\u03b1-Synulclein in Parkinson\u2019s disease","volume":"2","author":"Stefanis","year":"2012","journal-title":"Cold Spring Harb. Prospect."},{"issue":"1","key":"10.1016\/j.neuint.2013.06.005_b1055","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4161\/pri.23582","article-title":"The pathology roadmap in Parkinson disease","volume":"7","author":"Surmeier","year":"2013","journal-title":"Prion"},{"key":"10.1016\/j.neuint.2013.06.005_b1060","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/0971-6866.96639","article-title":"Genetic biomarkers of depression","volume":"18","author":"Tamatam","year":"2012","journal-title":"Indian J. Hum. Genet."},{"key":"10.1016\/j.neuint.2013.06.005_b1065","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.neuropharm.2011.01.006","article-title":"Serotonin-dependent depression in Parkinson\u2019s disease: a role for the subthalamic nucleus?","volume":"61","author":"Tan","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuint.2013.06.005_b1070","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.nbd.2009.11.004","article-title":"Neuroinflammation in Parkinson\u2019s disease: its role in neuronal death and implications for therapeutic intervention","volume":"37","author":"Tansey","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuint.2013.06.005_b1075","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2217\/bmm.10.111","article-title":"Circulating levels of brain-derived neurotrophic factor: correlation with mood, cognition and motor function","volume":"4","author":"Teixeira","year":"2010","journal-title":"Biomark Med."},{"key":"10.1016\/j.neuint.2013.06.005_b1090","article-title":"Biomarkers in Alzheimer\u2019s disease and Lewy body disorders with dementia","volume":"2013","author":"Thomas","year":"2013","journal-title":"Int. J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.neuint.2013.06.005_b1100","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1523\/JNEUROSCI.5575-11.2012","article-title":"Deficiency of ATP13A2 leads to lysosomal dysfunction, \u03b1-Syn accumulation, and neurotoxicity","volume":"32","author":"Usenovic","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuint.2013.06.005_b1105","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/brain\/awt022","article-title":"Sex, drugs and Parkinson\u2019s disease","volume":"136","author":"Ushe","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.neuint.2013.06.005_b1110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.nbd.2010.04.020","article-title":"Diagnostic cerebrospinal fluid biomarkers for Parkinson\u2019s disease: a pathogenetically based approach","volume":"39","author":"van Dijk","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuint.2013.06.005_b1115","doi-asserted-by":"crossref","first-page":"624925","DOI":"10.1155\/2012\/624925","article-title":"Oxidative stress in genetic mouse models of Parkinson\u2019s disease","volume":"2012","author":"Var\u00e7in","year":"2012","journal-title":"Oxid. Med. Cell Longev."},{"key":"10.1016\/j.neuint.2013.06.005_b1120","first-page":"3","article-title":"Application of mass spectrometry-based proteomics for biomarker discovery in neurological disorders","volume":"12","author":"Venugopal","year":"2009","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.neuint.2013.06.005_b1125","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/ana.21962","article-title":"Association of pyridoxal kinase and Parkinson disease","volume":"67","author":"Vilari\u00f1o-G\u00fcell","year":"2010","journal-title":"Ann. Neurol."},{"issue":"Suppl. 1","key":"10.1016\/j.neuint.2013.06.005_b1130","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/S1353-8020(11)70026-8","article-title":"Impulse control disorders in Parkinson\u2019s disease","volume":"18","author":"Vilas","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuint.2013.06.005_b1135","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-pharmtox-010611-134625","article-title":"Addiction circuitry in the human brain","volume":"52","author":"Volkow","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuint.2013.06.005_b1140","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.3390\/ijms11114257","article-title":"a-Syn and DJ-1 as potential biological fluid biomarkers for Parkinson\u2019s disease","volume":"11","author":"Waragai","year":"2010","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuint.2013.06.005_b1145","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1517\/17530059.2013.733694","article-title":"Biomarkers for the diagnosis and management of Parkinson\u2019s disease","volume":"7","author":"Waragai","year":"2013","journal-title":"Expert Opin. Med. Diagn."},{"key":"10.1016\/j.neuint.2013.06.005_b1150","first-page":"227","article-title":"Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson\u2019s disease","volume":"46","author":"Weintraub","year":"2005","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.neuint.2013.06.005_b1155","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients","volume":"67","author":"Weintraub","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuint.2013.06.005_b1165","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.metabol.2012.08.025","article-title":"Personalized medicine strategies for managing patients with parkinsonism and cognitive deficits","volume":"62","author":"Wurtman","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.neuint.2013.06.005_b1175","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10072-010-0340-3","article-title":"Proteomics analysis of MPP+-induced apoptosis in SH-SY5Y cells","volume":"32","author":"Xie","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuint.2013.06.005_b1180","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s12035-012-8327-0","article-title":"\u03b1-Syn and neuronal cell death","volume":"47","author":"Yasuda","year":"2013","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuint.2013.06.005_b1185","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.neulet.2009.03.037","article-title":"No association between polymorphism of serotonin transporter gene and depression in Parkinson\u2019s disease in Chinese","volume":"455","author":"Zhang","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuint.2013.06.005_b1190","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.neulet.2010.05.063","article-title":"Proteome analysis of the sera from Chinese Parkinson\u2019s disease patients","volume":"479","author":"Zhao","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuint.2013.06.005_b1200","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/jamaneurol.2013.597","article-title":"Substantia nigra volume loss before Basal forebrain degeneration in early Parkinson disease","volume":"70","author":"Ziegler","year":"2013","journal-title":"JAMA Neurol."}],"container-title":["Neurochemistry International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018613001678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018613001678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T16:11:46Z","timestamp":1715530306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197018613001678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":207,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0197018613001678"],"URL":"https:\/\/doi.org\/10.1016\/j.neuint.2013.06.005","relation":{},"ISSN":["0197-0186"],"issn-type":[{"value":"0197-0186","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers in Parkinson\u2019s disease (recent update)","name":"articletitle","label":"Article Title"},{"value":"Neurochemistry International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuint.2013.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}